Delivery of Therapeutic MiRNA Using Polymer-based Formulation

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2019 May 4

PMID 31049843

Citations 29

Authors

Eunmi Ban

Taek-Hyun Kwon

Aeri Kim

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs that play important roles in many cellular processes such as development, proliferation, differentiation, and apoptosis. For this reason, miRNAs have been proposed and investigated as biomarkers and therapeutics for various diseases such as cancer, diabetes, and cardiovascular disease. However, delivery of miRNAs and their antagomirs to target sites remains challenging because of poor cellular uptake and degradation by nucleases. Various delivery systems have been investigated for enhanced delivery of miRNAs to cells, organs, and tissues of interest, thereby enabling evaluation of their biological functions and clinical trials. In particular, non-viral, polymer-based carriers have shown advantages such as versatility of structural modifications and protection of unstable miRNA. Herein, we review properties and applications of poly (lactic-co-glycolic acid), chitosan, polyethyleneimine, and polyamidoamine dendrimers as carriers for effective delivery systems of miRNA mimic or anti-miRNAs that directly target essential miRNAs and/or their target genes. A number of miRNAs in clinical trials appear to use chemically modified miRNAs without any particular delivery system except one study with liposomal miRNA. With more accumulation of positive research results on polymeric delivery of miRNA in vitro and in vivo, we expect that polymeric delivery system will accelerate advancement of miRNA therapeutics to clinical study in the near future.

Citing Articles

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.

Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.

Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A Int J Nanomedicine. 2025; 20():25-52.

PMID: 39802382 PMC: 11717654. DOI: 10.2147/IJN.S429279.

MicroRNA-26a in respiratory diseases: mechanisms and therapeutic potential.

Liu X, Chen Q, Jiang S, Shan H, Yu T Mol Biol Rep. 2024; 51(1):627.

PMID: 38717532 DOI: 10.1007/s11033-024-09576-5.

MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage.

Gareev I, Beylerli O, Zhao B Biomark Res. 2024; 12(1):17.

PMID: 38308370 PMC: 10835919. DOI: 10.1186/s40364-024-00568-y.

miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.

Huang W, Paul D, Calin G, Bayraktar R Cells. 2024; 13(1).

PMID: 38201290 PMC: 10778542. DOI: 10.3390/cells13010084.

References

Yu W, Zheng Y, Yang Z, Fei H, Wang Y, Hou X . -AC-l-Leu-PEI-mediated miR-34a delivery improves osteogenic differentiation under orthodontic force. Oncotarget. 2018; 8(66):110460-110473. PMC: 5746396. DOI: 10.18632/oncotarget.22790. View

Fan W, Wang X, Ding B, Cai H, Wang X, Fan Y . Thioaptamer-conjugated CD44-targeted delivery system for the treatment of breast cancer in vitro and in vivo. J Drug Target. 2015; 24(4):359-71. DOI: 10.3109/1061186X.2015.1077850. View

Wang H, Zhao X, Guo C, Ren D, Zhao Y, Xiao W . Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. PLoS One. 2015; 10(9):e0139136. PMC: 4583438. DOI: 10.1371/journal.pone.0139136. View

Dai X, Tan C . Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev. 2014; 81:184-97. DOI: 10.1016/j.addr.2014.09.010. View

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

Van Rooij E, Kauppinen S . Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6(7):851-64. PMC: 4119351. DOI: 10.15252/emmm.201100899. View

Wu X, Tai Z, Zhu Q, Fan W, Ding B, Zhang W . Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo. Int J Nanomedicine. 2014; 9:5431-40. PMC: 4247134. DOI: 10.2147/IJN.S71101. View

Abdul Ghafoor Raja M, Katas H, Jing Wen T . Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. PLoS One. 2015; 10(6):e0128963. PMC: 4465927. DOI: 10.1371/journal.pone.0128963. View

Li Y, Dai Y, Zhang X, Chen J . Three-layered polyplex as a microRNA targeted delivery system for breast cancer gene therapy. Nanotechnology. 2017; 28(28):285101. DOI: 10.1088/1361-6528/aa757f. View

10.

Serr I, Furst R, Ott V, Scherm M, Nikolaev A, Gokmen F . miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A. 2016; 113(43):E6659-E6668. PMC: 5087025. DOI: 10.1073/pnas.1606646113. View

11.

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

12.

Du C, Yan H, Liang J, Luo A, Wang L, Zhu J . Polyethyleneimine-capped silver nanoclusters for microRNA oligonucleotide delivery and bacterial inhibition. Int J Nanomedicine. 2017; 12:8599-8613. PMC: 5716333. DOI: 10.2147/IJN.S146968. View

13.

de Araujo R, da Silva Santos S, Ferreira E, Giarolla J . New Advances in General Biomedical Applications of PAMAM Dendrimers. Molecules. 2018; 23(11). PMC: 6278347. DOI: 10.3390/molecules23112849. View

14.

Kaban K, Salva E, Akbuga J . In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. Nucleic Acid Ther. 2016; 27(1):45-55. DOI: 10.1089/nat.2016.0633. View

15.

Kulkarni A, Patel H, Surana S, Vanjari Y, Belgamwar V, Pardeshi C . N,N,N-Trimethyl chitosan: An advanced polymer with myriad of opportunities in nanomedicine. Carbohydr Polym. 2016; 157:875-902. DOI: 10.1016/j.carbpol.2016.10.041. View

16.

Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C . Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016; 44(8):3865-77. PMC: 4856985. DOI: 10.1093/nar/gkw116. View

17.

Meng Z, Zhou D, Gao Y, Zeng M, Wang W . miRNA delivery for skin wound healing. Adv Drug Deliv Rev. 2017; 129:308-318. DOI: 10.1016/j.addr.2017.12.011. View

18.

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

19.

Louw A, Kolar M, Novikova L, Kingham P, Wiberg M, Kjems J . Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury. Nanomedicine. 2015; 12(3):643-653. DOI: 10.1016/j.nano.2015.10.011. View

20.

Liang G, Zhu Y, Jing A, Wang J, Hu F, Feng W . Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model. Gene Ther. 2016; 23(12):829-838. DOI: 10.1038/gt.2016.60. View